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Cannabinoids exert pleiotropic actions in the CNS, including
the inhibition of inflammatory responses and the enhancement
of neuronal survival after injury. Although cannabinoid receptors
are distributed widely in brain, their presence has not been
investigated previously in oligodendrocytes. This study exam-
ined the expression of cannabinoid type 1 (CB1) receptors in rat
oligodendrocytes in vivo and in culture and explored their bio-
logical function. Expression of CB1 receptors by oligodendro-
cytes was demonstrated immunocytochemically in postnatal
and in adult white matter as well as in oligodendrocyte cultures.
Reverse transcription-PCR and Western blotting further con-
firmed the presence of CB1 receptors. Oligodendrocyte pro-
genitors undergo apoptosis with the withdrawal of trophic sup-
port, as determined by TUNEL assay and caspase-3 activation,
and both the selective CB1 agonist arachidonyl-2-chloroeth-
ylamide/(all Z)-N-(2-cycloethyl)-5,8,11,14-eicosatetraenamide
(ACEA) and the nonselective cannabinoid agonists HU210 and
()-Win-55212-2 enhanced cell survival. To investigate intracel-
lular signaling involved in cannabinoid protection, we focused
on the phosphatidylinositol-3 kinase (PI3K)/Akt pathway.
HU210, ()-Win-55212-2, and ACEA elicited a time-dependent
phosphorylation of Akt. Pertussis toxin abolished Akt activa-
tion, indicating the involvement of Gi /Go-protein-coupled re-
ceptors. The CB1 receptor antagonist SR141716A partially
inhibited Akt phosphorylation in response to HU210 and ()-
Win-55212-2 and abolished the effects of ACEA. Trophic sup-
port deprivation downregulated Akt activity, and cannabinoids
recovered phospho-Akt levels. Inhibition of PI3K abrogated the
survival action and the recovery of Akt activity in response to
cannabinoids. SR141716A prevented only the protection con-
ferred by ACEA. Nevertheless, SR141716A and the selective
CB2 receptor antagonist SR144528 in combination inhibited
the prosurvival action of HU210, which is in accordance with
the finding of CB2 receptor expression by oligodendroglial
cells. These data identify oligodendrocytes as potential targets
of cannabinoid action in the CNS.
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Synthetic and endogenous cannabinoids exert profound actions in
the CNS. Thus they modulate inflammatory and immune re-
sponses (Klein et al., 2000), inhibit pain (Pertwee, 2001), and
reduce neuronal damage in models of excitotoxicity (van der Stelt
et al., 2001), ischemia (Nagayama et al., 1999), and traumatic
brain injury (Panikashvili et al., 2001). Other studies have re-
ported anti-proliferative properties of cannabinoids on trans-
formed cells and the regression of malignant gliomas in experi-
mental models (Galve-Roperh et al., 2000).
To date, three endogenous lipids, derivatives of long-chain
fatty acids, have been isolated and characterized as natural li-
gands of cannabinoid receptors (Devane et al., 1992; Mechoulam
et al., 1995; Hanus et al., 2001). Two types of cannabinoid (CB)
receptors, CB1 and CB2, have been identified (Matsuda et al.,
1990; Munro et al., 1993), and recent evidence supports the
existence of additional receptors (Breivogel et al., 2001; Howlett
at al., 2002). CB1 receptors are concentrated in the CNS (Mat-
suda et al., 1993), whereas CB2 receptors are expressed in the
immune system (Munro et al., 1993). CB1 receptors are present in
developing and adult brain in regions involved in the control of
motor coordination, memory, and cognitive processes (Herken-
ham et al., 1991; Mailleux and Vanderhaeghen, 1992). CB1 re-
ceptors localize in dendritic spines and axon terminals (Ong and
Mackie, 1999) and modulate neuronal excitability (Huang et al.,
2001). However, reports on cannabinoids in glial cells are scarce,
and no studies addressing the expression and function of CB1
receptors in oligodendrocytes are presently available.
Cannabinoid receptors belong to the Gi/Go-protein-coupled
receptor superfamily (Pertwee, 1997). Cellular responses trig-
gered with receptor activation include inhibition of adenylyl
cyclase and voltage-gated calcium channels, increased transcrip-
tion of the immediate early gene krox-24, and activation of
potassium channels, mitogen-activated protein kinase (MAPK),
and phosphoinositide-3 kinase (PI3K)/Akt signaling pathways
(Bouaboula et al., 1995a,b; Go´mez del Pulgar et al., 2000). Acti-
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vated Akt phosphorylates intracellular substrates, and this pro-
vides a survival signal that protects cells from apoptosis induced
by various stresses (for review, see Brunet et al., 2001).
Survival and successful differentiation of proliferating oligo-
dendrocyte progenitors to myelinating oligodendrocytes require
contact with axons and trophic factors released by neurons and
glial cells (Barres et al., 1992, 1993; Gard et al., 1995; Fernandez
et al., 2000). In addition, oligodendrocytes are vulnerable to
various insults, and their damage strongly affects brain function
(Levine et al., 2001). Oligodendrocyte death is a prominent
feature in inflammatory diseases such as multiple sclerosis (Lass-
mann, 1998) and other demyelinating/hypomyelinating disorders
(Vela et al., 1998). However, oligodendrocyte progenitors exist in
mature CNS and are recruited to the demyelinated areas where
they remyelinate naked axons (Keirstead and Blakemore, 1999;
Chang et al., 2000). On this basis, the identification of endoge-
nous signals that promote oligodendrocyte progenitor survival
may contribute to developing reparative strategies in demyelinat-
ing diseases. The objectives of the present study were to evaluate
the expression of cannabinoid CB1 receptors in oligodendrocytes
in vivo and in culture and to gain insights into the underlying
physiological function of these receptors in conditions in which
oligodendrocyte survival is compromised.
MATERIALS AND METHODS
Reagents. Culture media and fetal calf serum (FCS) were from Invitrogen
(Barcelona, Spain). Human recombinant platelet-derived growth
factor-AA (PDGF-AA) and basic fibroblast growth factor (bFGF) were
from PeproTech (London, UK). The astrocytic marker anti-glial fibril-
lary acidic protein (GFAP) and anti--tubulin were from Sigma (Madrid,
Spain), and OX-42 antibody was obtained from Serotec (Oxford, En-
gland). The antibody against Akt was from Santa Cruz Biotechnology
(Santa Cruz, CA). Affinity-purified rabbit antibodies against phospho-
Akt (Ser 473), phospho-GSK-3 (Ser 9), and cleaved caspase-3 were from
Cell Signaling Technology (Beverly, MA). Monoclonal anti-glycogen
synthase kinase-3 (GSK-3) was from BD Transduction Laboratories
(San Diego, CA). The affinity-purified polyclonal anti-CB1 receptor
antibody was obtained from Calbiochem (Darmstadt, Germany), and
the CB2 receptor antibody was from Cayman Chemical (Ann Arbor,
MI). The oligodendrocyte antibody anti-myelin basic protein (MBP) was
from Sternberger Monoclonals (Lutherville, MD), and the anti-
oligodendrocyte monoclonal antibody (RIP clone) was from Chemicon
(Temecula, CA). The secondary peroxidase-conjugated anti-mouse or
anti-rabbit antibodies were from Bio-Rad (Hercules, CA) and Jackson
ImmunoResearch Laboratories (West Grove, PA), respectively. The
secondary antibodies for immunofluorescence anti-rabbit IgG-Alexa 594
or 488 and anti-mouse IgG-Alexa 488 or 594 were from Molecular Probes
(Eugene, OR), the biotinylated anti-rabbit IgG was from Amersham
Biosciences (Barcelona, Spain), and the avidin-peroxidase was from
Dako (Barcelona, Spain). The cannabinoids ()Win 55,212-2 and
arachidonyl-2-chloroethylamide/(all Z)-N-(2-cycloethyl)-5,8,11,14-eico-
satetraenamide (ACEA) and the PI3K inhibitors LY294002 and wort-
mannin were from Tocris Cookson (Bristol, UK). HU210 was a generous
gift from Professor Raphael Mechoulam (Hebrew University, Jerusalem,
Israel). All other reagents were obtained from standard suppliers.
Tissue processing and immunohistochemistry. Animals used in this
study were postnatal (P0, P5, P9, P15) and adult (90 d old) rats of the
Wistar strain, three per group. All efforts were made to minimize animal
suffering, and experimental animal procedures were conducted in com-
pliance with Spanish legislation and according to the European Union
directives on this subject (86/609/EEC).
Animals were anesthetized with sodium pentobarbital (50 mg/kg body
weight) and transcardially perfused with 4% paraformaldehyde in 0.1 M
phosphate buffer (PB). Brains were dissected out and immersed for an
additional 4 hr at room temperature (RT) in the same fixative. Then
brains were washed in PB and sliced in 40-m-thick coronal sections with
a vibratome. Tissue sections were rinsed 3  5 min in TBS (50 mM
Tris-HCl containing 150 mM NaCl), pH 7.4, treated for 10 min with 2%
hydrogen peroxide in 100% methanol to block endogenous peroxidase,
and rinsed again 3  5 min in TBS with 0.1% Triton X-100 (TBS-T).
Sections then were placed for 30 min at RT in blocking buffer (BB;
TBS-T containing 10% FCS) and incubated overnight at 4°C with a
rabbit anti-CB1 receptor antibody raised against the N-terminal 14
amino acids of the rat CB1 receptor (1:1000 in BB). After being rinsed
3  5 min in TBS-T, the sections were incubated for 60 min at RT with
anti-rabbit IgG-biotinylated secondary antibody (1:200 in BB), rinsed
again, and incubated for 60 min at RT with avidin-peroxidase (1:400 in
BB). After rinsing, the peroxidase reaction was visualized by transferring
the sections to 100 ml of TBS containing 50 mg of 3,3-diaminobenzidine-
4HCl (DAB) and 33 l of hydrogen peroxide for 5 min. Finally, the
sections were rinsed, mounted on gelatin-coated slides, dehydrated in
graded ethanol, cleared in xylene, and coverslipped in DPX. As a
negative control for immunocytochemical staining, the primary antibody
was omitted in some sections per animal for each age.
Simultaneous visualization of CB1 receptor expression and oligoden-
drocytes was achieved by double immunofluorescence that combined the
CB1 receptor antibody and RIP, an anti-oligodendrocyte-specific anti-
body. Vibratome sections were immunostained for the CB1 receptor as
described previously but with the use of a 1:1000 dilution of Alexa Fluor
594-conjugated anti-rabbit IgG as a secondary antibody. After being
rinsed, the sections were incubated overnight at 4°C with RIP (1:100,000
in BB), rinsed again, and incubated with the secondary Alexa Fluor
488-conjugated anti-mouse IgG (1:1000). Finally, the sections were
rinsed, mounted on gelatin-coated slides, and coverslipped in fluorescent
mounting medium (Shandon-Lipshaw, Pittsburgh, PA). As a negative
control, primary antibodies were omitted. Sections were analyzed by
confocal laser microscopy.
Purification and culture of oligodendrocyte progenitors. Primary mix
glial cultures were prepared as described previously (Almazan et al.,
1993; Molina-Holgado et al., 2001) according to the modified technique
of McCarthy and de Vellis (1980). Briefly, forebrains of newborn Wistar
rats were dissociated mechanically, filtered through a 150 m nylon
mesh, resuspended in DMEM containing 12% heat-inactivated FCS, and
plated on poly-L-ornithine-coated (15 g/ml) 75 cm 2 flasks (Nunc, Wies-
baden, Germany). After 10 d in culture the flasks were shaken at 225 rpm
at 37°C for 3 hr to remove loosely adherent microglia. The supernatant
was plated on bacterial grade Petri dishes for 2 hr, and the adherent
microglial cells were detached and replated onto uncoated tissue culture
dishes to obtain a 98% pure microglial culture according to OX-42
staining. The remaining oligodendrocyte progenitors present on the top
of the confluent monolayer of astrocytes were dislodged by shaking
overnight at 260 rpm. The cell suspension was filtered through a 10 m
nylon mesh and then preplated on bacterial grade Petri dishes for 2 hr.
The nonadherent oligodendrocyte progenitors that remained in suspen-
sion were recovered and plated again on bacterial grade Petri dishes for
1 hr. The resulting enriched oligodendrocyte progenitor cell suspension
was plated onto poly-D-lysine-coated (PDL; 5 g/ml) six-well (9.6 cm 2/
well) and 24-well (2 cm 2/well) tissue culture dishes and glass coverslips at
a density of 25  10 3 cells/cm 2 and cultured for 2 d before experiments
in serum-free defined medium (SFM) containing 5 ng/ml PDGF-AA plus
5 ng/ml bFGF. The SFM used in oligodendroglial cultures consisted of
DMEM supplemented with (in nM) 30 triiodothyronine, 20 hydrocorti-
sone, 20 progesterone, 10 D-biotin, and 30 selenium, plus 25 g/ml
apo-transferrin, 10 g/ml insulin, 1 g/ml putrescine, 0.1% BSA, 50
U/ml penicillin, and 50 U/ml streptomycin. To promote the differentia-
tion of oligodendrocyte progenitors to MBP-positive oligodendrocytes,
we switched the cultures to SFM without mitogenic growth factors for an
additional 5 d. The purity of oligodendroglial cultures was assessed by
examining the characteristic cell morphologies under phase-contrast
microscopy and was confirmed by immunostaining with antibodies
against oligodendroglial cell-specific markers as described below. After
2 d in culture the A2B5-positive oligodendrocyte progenitors represented
98  2% of total cells (means  SEM; n  10 independent cultures; two
coverslips per culture, five microscopic field per coverslip; total cells
counted, 26,300). In cultures that were differentiated for 5 d, 96.5 0.5%
of the total cells were MBP-positive (n  10 cultures; total cells counted,
18,343). Astrocyte cultures, 99% glial fibrillary acidic protein (GFAP)-
positive cells, were obtained after removing the oligodendrocyte progen-
itors present on the top of the astrocyte monolayer by extensive shaking;
cultures were trypsinized and replated in tissue culture six-well dishes for
an additional 3 d to obtain total RNA and protein extracts.
Immunocytochemistry in cultured cells. For immunostaining of oligo-
dendrocyte progenitors and microglial surface antigens, live cells plated
onto PDL-coated coverslips were incubated for 15 min at RT with the
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mouse monoclonal antibodies A2B5 (culture supernatants diluted 1:10)
or OX-42 (1:200). After being rinsed with PBS, the cells were incubated
for 15 min at RT with secondary Alexa-conjugated (Alexa 488 or Alexa
594) anti-mouse IgM or IgG. Then the coverslips were washed with PBS,
fixed with 4% paraformaldehyde, and mounted on slides or processed for
double labeling. For cleaved (active) caspase-3, MBP, GFAP, CB1, and
CB2 receptor immunocytochemistry, the fixed cells were incubated over-
night at 4°C with anti-MBP (1:5000), anti-GFAP (1:1000), anti-CB1
(1:1500), anti-CB2 (1:2000), or anti-cleaved caspase-3 (1:200) diluted in
PBS containing 5% FCS and 0.1% Triton X-100. Coverslips then were
rinsed and incubated for 2 hr at RT with 1:1500 anti-rabbit or anti-mouse
IgGs conjugated with Alexa 488 or Alexa 594. Nonspecific interactions of
secondary antibodies were verified by omitting the primary antibodies.
The nuclei were labeled with bis-benzimide (Hoechst 33258; 1 g/ml for
10 min at RT). Double labeling combining A2B5/CB1, A2B5/CB2, A2B5/
OX42, A2B5/GFAP, A2B5/caspase-3, MBP/CB1, and MBP/CB2 was
performed by a combination of the described technical procedures.
Coverslips were mounted on glass slides with fluorescent mounting
medium. For cell counting the preparations were visualized under a
Zeiss Axiovert (Oberkochen, Germany) fluorescent microscope with a
40 objective. At least three independent cultures were examined for
each antibody; five microscopic fields were counted per coverslip and two
coverslips per culture.
Withdrawal of trophic support and cell viabilit y experiments. Oligoden-
drocyte progenitors grown for 2 d in serum-free defined medium plus 5
ng/ml PDGF/bFGF (controls) were switched overnight (12 hr) or in
DMEM/F12 with or without cannabinoids. After such treatment the
oligodendrocyte progenitor survival was quantified by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and
by lactate dehydrogenase (LDH) activity released from damaged cells.
The MTT reaction is based on the cleavage of the tetrazolium ring by
active mitochondria of viable cells into a dark blue formazan product.
MTT was dissolved in PBS and used at a concentration of 0.5 mg/ml.
After 2 hr of incubation at 37°C, acidic isopropanol was added to dissolve
the formazan crystals, and the absorbance was read at 595 nm. Data are
presented as a percentage relative to their corresponding controls. The
release of LDH into the culture supernatant representing cell lysis was
assessed with a commercial LDH kit (Roche Molecular Biochemicals,
Mannheim, Germany). LDH values were calculated relative to total LDH
content measured after the cells were lysed completely by 1% Triton
X-100. In addition, the percentage of surviving oligodendrocyte progen-
itors in the presence or absence of cannabinoids was established by
counting A2B5-positive progenitors; the results were expressed over the
total nuclei stained with bis-benzimide.
Apoptosis of oligodendrocyte progenitors was measured by nuclear
DNA staining, TUNEL assay, and caspase-3 immunocytochemistry.
Morphological changes in the nuclear chromatin of oligodendrocyte
progenitors undergoing apoptosis was detected by staining with bis-
benzimide (1 g/ml), and the number of pyknotic nuclei was determined
by examination on a fluorescence microscope. Apoptotic nuclei also were
Figure 1. Oligodendroglial cells express
CB1 receptors in vivo and in culture.
Shown is double immunostaining with the
oligodendrocyte monoclonal antibody
RIP (A, green) and anti-CB1 receptor (B,
red) in P9 rat corpus callosum. Also
shown is double immunocytochemistry of
cultured oligodendrocyte progenitors with
A2B5 (D, green) and anti-CB1 receptor
(E, red). Differentiated oligodendrocytes
were double labeled with anti-MBP (G,
green) and anti-CB1 receptor (H, red). C,
F, I, L, O, Overlays of oligodendroglial
markers and CB1 receptors. Magnifica-
tions show an oligodendrocyte progenitor
( J–L) and a differentiated oligodendro-
cyte ( M–O) expressing CB1 receptors in
culture. Scale bars, A–C, 50 m; D–I, 40
m; J–O, 20 m.
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detected by using the terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) technique. Oligodendrocyte progenitors were
stained with A2B5 antibody, fixed with 4% paraformaldehyde in PBS for
30 min at RT, and permeabilized with 0.1% Triton X-100 and 0.1%
sodium citrate for 2 min on ice. After washing, in situ labeling of nuclear
DNA fragmentation was performed as described previously (Molina-
Holgado et al., 2001). Coverslips were washed two times in PBS and fixed
with 4% paraformaldehyde in PBS for 30 min at RT. Cells were rinsed,
treated with 0.1% Triton X-100 in 0.1% sodium citrate, and rinsed again
with PBS. Cells then were transferred for 10 min to a reaction buffer (30
mM Tris-HCl, 140 mM sodium cacodylate, 1 mM cobalt chloride), pH 7.2,
and incubated for 45 min at 37°C in a reaction buffer containing 0.3 U/l
terminal deoxynucleotidyl transferase and 20 M biotinylated 16-dUTP.
After being rinsed, the cells were incubated for 60 min at RT with a 1:500
dilution of avidin that was conjugated with fluorescein, rinsed, and
mounted on slides. The viable oligodendrocyte progenitors were quan-
tified by counting condensed bis-benzimide nuclei and TUNEL- and
caspase-positive cells; the results are expressed as percentage of the total
cells determined by bis-benzimide labeling.
Western blot analysis. After treatments the oligodendrocyte progeni-
tors were washed with ice-cold PBS and lysed in 60 l of TBS, pH 7.6,
containing 10% glycerol, 1% Nonidet P-40, and (in mM) 1 EDTA, 1
EGTA, 1 PMSF, 5 benzamidine, 1 sodium orthovanadate, 2 NaF, and 5
DTT plus 50 g/ml leupeptin and 10 g/ml aprotinin. Cell lysates were
mixed with 5 Laemmli sample buffer and boiled for 4 min. Then equal
amounts of protein (25 g) were resolved on 10% SDS-PAGE and
electroblotted for 1 hr at 4°C to nitrocellulose (Amersham Biosciences).
The membranes were blocked for 1 hr at RT in 5% (w/v) dry skim milk
(Sveltese, Nestle´, Barcelona, Spain) in TBS plus 0.1% Tween 20 (TBST);
then the blots were rinsed in TBST. The membranes were incubated
overnight with anti-phospho (Ser 473) Akt (1:1000), anti-Akt (1:4000),
anti-GSK-3 (1:3000), or anti-phospho (Ser 9) GSK-3 (1:1000). After
extensive washing in 5% milk-TBST solution, the blots were incubated
with peroxidase-conjugated anti-rabbit (1:15,000) or anti-mouse (1:8000)
secondary antibodies for 1 hr at RT. Finally, the blots were rinsed, and
the peroxidase reaction was developed by enhanced chemiluminescence
(Amersham Biosciences). The blots were stripped in 62.5 mM Tris-HCl,
pH 6.8, containing 2% SDS and 0.7% -mercaptoethanol and were
reprobed sequentially.
Reverse transcriptase-PCR analysis. Cells grown in 9.6 cm 2 dishes were
washed twice with PBS, and total RNA was isolated by the guanidium
isothiocyanate/phenol /chloroform method. RNA was quantified spectro-
photometrically and treated with DNase to digest any contaminating
genomic DNA. RT-PCR was performed in one step by using the Titan
one-tube RT-PCR system according to the manufacturer’s instructions
(Roche Molecular Biochemicals) with 2 g of RNA. The CB1 receptor
primers were 5-TATATTCTCTGGAAGGCTCACAGCC and 5-
GAGCATACTGCAGAATGCAAACACC (Bouaboula et al., 1995a).
Reactions were performed in a thermal cycler, with 50°C reverse tran-
scription for 30 min, and the following PCR amplification steps: 94°C
denaturation for 30 sec, 64°C primer annealing for 30 sec, and 68°C
elongation for 40 sec for 25 cycles (Molina-Holgado et al., 2002). The
PCR products were resolved on 2% agarose gels containing ethidium
bromide; the CB1 transcript was identified as a 270 bp band.
Glyceraldehyde-3 phosphate dehydrogenase (GAPDH) was used as an
internal standard (data not shown). As a control for DNA contamination,
PCR was performed on each sample, omitting the reverse transcriptase
step.
Statistical analysis. Results are presented as the means  SEM of at
least three different experiments performed in separate cell preparations;
duplicate or triplicate determinations were performed in each experi-
ment. One-way ANOVA, followed by a posteriori Tukey’s multiple
comparison test was used to examine the statistical significance; p val-
ues  0.05 were considered significant.
RESULTS
Cannabinoid CB1 receptors are expressed by
oligodendrocytes in vivo and in culture
In the adult CNS, CB1 receptor immunoreactivity is concen-
trated mostly in afferent axon terminals around neuronal surfaces
as well as on neuronal cell bodies and dendrites in different brain
areas (Ong and Mackie, 1999). However, the presence of CB1
receptors is not restricted to neurons, because we found a
moderate-to-weak immunostaining in white matter areas. Cells
tended to be arranged in rows, and on the basis of double
immunocytochemistry they were identified as oligodendroglial
cells (Fig. 1A–C). All of the different developmental stages, that
is, progenitors found at early postnatal times, differentiating oli-
godendrocytes found by the second postnatal week, and differen-
Figure 2. Expression of cannabinoid CB1 receptor in cultured brain glial
cells. A, Total RNA was extracted from purified cultures of oligodendro-
cyte progenitors, differentiated oligodendrocytes, microglial cells, and
astrocytes. RT-PCR amplification was performed with specific CB1 prim-
ers that used 2 g of RNA, as described in Materials and Methods. B, The
expression of CB1 receptor protein also was demonstrated by Western
blot analysis (anti-CB1 diluted to 1:1500) of whole-cell lysates (25 g of
protein). CB1 mRNA and protein levels in progenitors and differentiated
oligodendrocytes appeared relatively higher than in microglia and astro-
cytes. OP, Oligodendrocyte progenitors; OL, differentiated oligodendro-
cytes; mi, microglia; AST, astrocytes.
Table 1. Effect of cannabinoids on oligodendrocyte progenitor survival after deprivation of trophic support
Treatment
A2B5 cells
(% of control)
MTT assay
(% of control)
LDH release
(% of total)
TUNEL cells
(% of total)
Condensed nuclei
(% of total)
Caspase-3 cells
(% of total)
CTL (PDGF  bFGF) 100  2.6 100 3.5 3.33  0.8 2.18  0.2 1.3 0.6 1.67  0.6
DMEM  F12 (DF) 53.6  5.1* 56.3 1.2* 34.3  5.8* 23.7  1.5* 18.0 1.6* 20.2 1.8*
DF  HU210 80.4 5.7 80.3  2.6# 8.00  1.0# 3.70  0.3# 2.30  0.3# 2.36  0.3#
DF  Win 55212-2 83.0 6.4 86.3  2.2# 10.6  0.8# 4.40  0.4# 3.20  0.3# 1.78  0.4#
Oligodendrocyte progenitors were cultured for 2 d in serum-free defined medium plus 5 ng/ml of both PDGF and bFGF and then switched to DMEM/F12 (DF) medium alone
without growth supplements for 12 hr in the presence or absence of the nonselective cannabinoid agonists HU210 (500 nM) or ()-Win 55212-2 (25 nM). The MTT and LDH
data are the mean  SEM of four independent experiments performed in triplicate. Quantification of condensed nuclei, A2B5-, TUNEL-, and caspase-3-positive cells was
obtained from at least eight coverslips (5 microscopic fields/coverslip), and results are the mean  SEM of four independent cultures. A minimum of 1500 cells was counted
per coverslip. Statistical differences: *p  0.001 DMEM  F12 (DF) versus control cells (with PDGF and bFGF); #p  0.001 DF  HU210 or DF  Win55212-2 versus DF;
p  0.01 DF  HU210 or DF  Win55212-2 versus DF.
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tiated oligodendrocytes in the adult, expressed CB1 receptors
(data not shown). Oligodendroglial were the cells showing the
highest immunoreactivity in white matter at all of the ages that
were analyzed; however, we cannot rule out the possibility that
other glial cells might express CB1 receptors in vivo.
The expression of CB1 receptors in cultured progenitors and
differentiated oligodendrocytes was investigated by immunocyto-
chemistry, Western blotting, and RT-PCR. Results from double-
immunofluorescent labeling revealed that both A2B5-positive
oligodendrocyte progenitors and MBP-positive differentiated oli-
godendrocytes expressed CB1 receptors (Fig. 1D–I). RT-PCR
analysis that used specific CB1 oligonucleotide primers (Bouaboula
et al., 1995a) showed an 	270 bp band, as expected (Fig. 2A), in
progenitor and differentiated oligodendrocytes. Similarly, expres-
sion of CB1 receptor protein was detected by Western blot analysis
in progenitor and differentiated cultures (Fig. 2B). This was evi-
denced by the presence of a prominent immunostained band with
a molecular mass of 	55 kDa, consistent with other reports (Mat-
suda et al., 1990). RNA and protein also were isolated from
microglial and astroglial cultures to compare the expression levels
of CB1 receptors among the different glial cells. Samples were
processed simultaneously, and the experimental conditions for the
Western blot and RT-PCR were strictly maintained. Our results, in
line with the in vivo observations, revealed that oligodendrocyte
progenitors and differentiated oligodendrocytes expressed rela-
tively higher levels of brain cannabinoid receptor mRNA and
protein than microglia and astrocytes (Fig. 2).
Cannabinoids protect oligodendrocyte progenitors
from apoptosis
To assess the effect of cannabinoids on oligodendrocyte progen-
itor survival, we cultured cells for 2 d in serum-free defined
medium plus 5 ng/ml of PDGF and FGF and then switched to
DMEM/F12 medium alone without growth supplements for 12
hr in the presence or absence of the nonselective cannabinoid
agonists HU210 (500 nM) or ()-Win 55212-2 (25 nM). With-
drawal of trophic support resulted in a marked reduction of
oligodendrocyte progenitor viability, as evidenced by cell count-
ing of A2B5-positive progenitors, MTT assay, and LDH release
to the culture media. As shown in Table 1, the decreased survival
measured by MTT assay and cell counting (	40%) was in close
agreement with the increased LDH activity in the media of
deprived cultures. Interestingly, trophic deprivation-mediated
cell death was prevented significantly when oligodendrocyte pro-
genitors were treated with the cannabinoid agonists HU210 or
()-Win 55212-2. Cannabinoids increased MTT values and the
number of surviving A2B5-positive oligodendrocyte progenitors
by 	50% while they decreased LDH release (Table 1).
Cell death was characterized morphologically by a loss of cell
processes and a shrinkage of the cell body (Fig. 3). The presence
in the culture supernatants of cellular debris and shrunken dead
cells detached from the substrate paralleled the reduction in cell
numbers and was consistent with the increased LDH activity in
the culture media. To characterize further the oligodendrocyte
progenitor death in our experimental paradigm, we performed
Figure 3. Cannabinoids protect oligo-
dendrocyte progenitors from apoptosis in-
duced by withdrawal of trophic support.
A, Phase-contrast images of live cells
showing the effects of HU210 (500 nM) or
()-Win 55,212-2 (25 nM) on cultures de-
prived of trophic support. B, Photomic-
rographs showing the reduction of
TUNEL ( green) oligodendrocyte pro-
genitors (A2B5; red) in cultures de-
prived of trophic support and treated with
HU210 or ()-Win 55,212-2. C, Immuno-
reactivity of active caspase-3 (red) in oli-
godendrocyte progenitors (A2B5; green)
deprived of trophic support and treated
with HU210 and ()-Win 55,212-2. D, E,
Arrows indicate oligodendrocyte progeni-
tors (A2B5; red or green) that display
condensed chromatin (bis-benzimide;
blue), DNA fragmentation (TUNEL;
green), or active caspase-3 immunostaining
(red). Scale bars: A–C, 50 m; D, E, 10 m.
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nuclear Hoechst 33258 staining and TUNEL to detect chromatin
condensation and DNA fragmentation, respectively. Figure 3, B
and D, shows that trophic deprivation induced the appearance of
TUNEL-positive oligodendrocyte progenitors displaying mor-
phological signs of apoptosis: nuclear condensation and fragmen-
tation (karyorhexis). Approximately 20% of oligodendrocyte pro-
genitors were TUNEL-positive after 12 hr of trophic support
deprivation, whereas5% of cells showed DNA fragmentation in
the presence of HU210 or ()-Win 55212-2 (Table 1). Because
the TUNEL method does not distinguish unambiguously be-
tween apoptosis and necrosis, we investigated caspase-3 expres-
sion by immunocytochemistry. Cleavage of pro-caspase 3 to an
active 17 kDa protease has been implicated in the execution of
oligodendrocyte apoptosis (Gu et al., 1999). Colocalization of the
active form of caspase-3 (17 kDa) and A2B5 was found in starved
cultures, particularly on cells exhibiting nuclear condensation
(Fig. 3C,E). In line with the above results, HU210 and ()-Win
55212-2 significantly reduced caspase-3 immunoreactivity after
trophic support deprivation (Table 1; Fig. 3C). Therefore, these
results indicate that oligodendrocyte progenitors are highly vul-
nerable to trophic factor deprivation and that cannabinoids pro-
tect progenitor cells from the apoptosis induced by such a
deprivation.
Cannabinoids induce Akt activation in
oligodendrocyte progenitors via a Gi/Go-protein- and
PI3K-dependent pathways
We next investigated whether cannabinoids activate the serine/
threonine kinase Akt, because this pathway has been implicated
in oligodendrocyte progenitor survival (Vemuri and McMorris,
1996; Ebner et al., 2000). This objective was accomplished by
immunoblotting whole-cell extracts with phospho-specific anti-
Akt (Ser473) antibody, because phosphorylation of this residue is
required for the kinase activity of Akt (Chan et al., 1999).
Exposure of progenitors to the nonselective agonists HU210 (500
nM) and ()-Win 55212-2 (25 nM) or to the selective CB1 agonist
ACEA (25 nM) caused a time-dependent phosphorylation of Akt
(Fig. 4A). The three cannabinoids induced a rapid (5 min) and
sustained (60 min) phosphorylation of Akt. To determine down-
Figure 4. Cannabinoids produce a time-dependent phosphorylation of
Akt and GSK-3. Oligodendrocyte progenitors were stimulated with
cannabinoid agonists in DMEM containing 1% FCS for different time
periods: 5, 30, and 60 min (A) or 10 min (B). Western blot analysis was
performed with antibodies specific for phospho-Akt (Ser 473) and
phospho-GSK-3 (Ser 9). The antibodies were stripped off, and the mem-
branes were reprobed with antibodies recognizing the total antigen (phos-
phorylated and unphosphorylated). Immunoblots in A also were analyzed
by densitometry (top right); the values are expressed as the means  SEM
of three independent experiments performed in duplicate.
Figure 5. Inhibition of PI3K results in the blockade of cannabinoid-
induced phosphorylation of Akt and GSK-3. A, Whole-cell lysates were
prepared and immunoblotted as described in Materials and Methods with
antibodies that recognize phospho-Akt (Ser 473), phospho-GSK-3
(Ser 9), and total Akt and GSK-3. B, Oligodendrocyte progenitors were
treated for 30 min with either 100 nM wortmannin or 10 M LY294002 and
then stimulated for 10 min with the nonselective cannabinoids HU210
(500 nM) and ()-Win 55,212-2 (25 nM). The densitometric data represent
the means  SEM of three independent experiments performed in
duplicate. *p  0.001 versus control untreated cells; #p  0.001 versus
HU210- or ()-Win 55,212-2-stimulated cultures.
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stream events involved in activated Akt signaling, we focused on
GSK-3 because Akt at Ser-9 phosphorylates this enzyme and its
phosphorylation inhibits its kinase activity (Cross et al., 1995).
We found that stimulation with all three cannabinoids increased
Ser-9 phosphorylation of GSK-3 at 10 min (Fig. 4B).
It is well established that Akt is a downstream target of PI3K.
We therefore examined the role of PI3K on cannabinoid-
mediated Akt activation by pretreating cultures with PI3K inhib-
itors. The two structurally distinct inhibitors that were used,
wortmannin (100 nM) and LY294002 (10 M), significantly re-
duced the cannabinoid-induced increases in Akt and GSK-3
phosphorylation (Fig. 5A,B).
Our immunocytochemical, Western blotting, and RT-PCR
data demonstrated the presence of CB1 receptors in oligoden-
drocyte progenitors, which couple to signal transduction pathways
via pertussis toxin (PTX)-sensitive Gi/Go-proteins (Pertwee,
1997). To determine whether the stimulatory effect of cannabi-
noids on Akt is a Gi/Go receptor-mediated process, we incubated
cells overnight with PTX (100 ng/ml) before exposure to HU210
(500 nM) or ()-Win 55212-2 (25 nM). Under these conditions the
phosphorylation of Akt stimulated by HU210 or ()-Win
55212-2 was prevented completely (Fig. 6A). Furthermore, to
investigate the involvement of CB1 receptors in cannabinoid-
induced Akt phosphorylation, we preincubated the cultures for 50
min with the CB1 receptor-selective antagonist SR141716A
(Rinaldi-Carmona et al., 1994). As shown in Figure 6B, the
stimulatory effects of HU210 (500 nM) and ()-Win 55212-2 (25
nM) on Akt phosphorylation were blocked partially by 1 M
SR141716A, whereas the CB1 antagonist abolished the effect of
ACEA (25 nM). Taken together, these results indicate that can-
nabinoids, acting on CB1 receptors, are able to activate Akt via
PTX-sensitive Gi/Go-proteins and via a PI3K-dependent signal-
ing pathway.
Promotion of oligodendrocyte progenitor survival by
cannabinoids requires PI3K/Akt activity
Activation of PI3K/Akt mediates cell survival in various cell
death paradigms (Brunet et al., 2001). The data presented so far
indicate that cannabinoids prevent oligodendrocyte progenitor
apoptosis and that these cells express functional cannabinoid
receptors linked to a PI3K/Akt signaling pathway. Therefore, to
determine whether the survival-promoting effect of cannabinoids
requires the PI3K/Akt pathway, we pretreated cells with specific
PI3K inhibitors. As shown in Figure 7A, oligodendrocyte progen-
itors cultured for 2 d in medium with growth factors contained
high levels of phosphorylated (activated) Akt. Withdrawal of
trophic support resulted in a marked decrease of phospho-Akt
steady-state levels, whereas the addition of either HU210 (500
nM) or ()-Win 55212-2 (25 nM) to the cultures during the
starvation period promoted a significant recovery of phospho-Akt
levels. Phosphorylation of Akt correlated with an increased Akt
activity as measured by the increased phosphorylation at Ser-9 of
GSK-3, one of its downstream substrates (Fig. 7A). Moreover,
inhibition of PI3K with 10 M LY294002 abolished the stimula-
tory effect of cannabinoids on Akt and GSK-3 phosphorylation
(Fig. 7A). Similar results were obtained with 100 nM wortmannin
(data not shown). We next investigated whether the prosurvival
effect of cannabinoids is dependent on PI3K/Akt activity. Cell
viability was monitored by MTT assay and the quantification of
A2B5-positive progenitors. We found that preincubation of cul-
tures with either 10 M LY294002 or 100 nM wortmannin pre-
vented the protection afforded by HU210 (500 nM) and ()-Win
55212-2 (25 nM) to oligodendrocyte progenitors (Fig. 7B).
Possible involvement of CB2 receptors in the
prosurvival action of cannabinoids
To evaluate the receptor subtype involved in the prosurvival
action of cannabinoids, we pretreated starved cultures with the
selective CB1 receptor antagonist SR141716A (1 M) before
agonist exposure. SR141716A did not block the effects of HU210
or ()-Win 55212-2, whereas it was effective in preventing the
survival action of ACEA (Fig. 8A). We further investigated the
Figure 6. The phosphorylation of Akt in response to cannabinoids is
PTX-sensitive and partially dependent on CB1 receptors. Oligodendro-
cyte progenitors were incubated for 12 hr with 100 ng/ml pertussis toxin
(A) or were pretreated for 50 min with 1 M of the CB1 receptor
antagonist SR141716A, followed by 10 min of stimulation with the selec-
tive CB1 agonist ACEA (20 nM) or with the nonselective cannabinoids
HU210 (500 nM) and ()-Win 55,212-2 (25 nM) (b). Whole-cell lysates
were prepared and immunoblotted as described in Materials and Methods
with antibodies that recognize phospho-Akt (Ser 473) and total Akt pro-
tein. The densitometric data represent the means  SEM of three
independent experiments performed in duplicate. A, *p  0.001 versus
control untreated cells; #p  0.001 versus HU210- or ()-Win 55,212-2-
stimulated cultures. B, *p  0.001 versus control untreated cells; #p 
0.001 versus HU210-, ()-Win 55,212-2-, or ACEA-stimulated cultures.
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effect of the selective CB2 antagonist SR144528. Interestingly,
SR144528 (1 M) did not block the effect of HU210, whereas the
coincubation of cultures with both antagonists abolished the
prosurvival effect of this cannabinoid (Fig. 8B). We then exam-
ined whether oligodendroglial cells express CB2 receptor protein.
As shown in Figure 9A, Western blotting analysis of both cultured
progenitors and differentiated oligodendrocytes revealed the
presence of a band of 	40 kDa corresponding to the predicted
molecular mass of the CB2 receptor (Carlisle et al., 2002). Sim-
ilarly, positive immunostaining for the CB2 receptor was found in
both cell types (Fig. 9B). Overall, the data that are presented
suggest that the protection conferred by cannabinoids after tro-
phic support deprivation involves the activation of the PI3K/Akt
signaling pathway and both CB1 and CB2 cannabinoid receptors.
DISCUSSION
The present study demonstrates that oligodendrocytes express
cannabinoid CB1 receptors in vivo and in culture and provides the
first evidence that the activation of these receptors protects oli-
godendrocyte progenitors from apoptosis produced by depriva-
tion of trophic support via a mechanism dependent on the PI3K/
Akt signaling pathway.
CB1 receptors were found in high concentrations in relation to
neurons. According to the presynaptic and postsynaptic location
of neuronal CB1 receptors (Ong and Mackie, 1999), immunore-
activity was concentrated on afferent axon terminals, neuronal
cell bodies, and dendrites. The relevant observation in this study
was the expression of cannabinoid CB1 receptors by oligodendro-
glial cells. The presence of CB1 receptors has not been reported
previously in individual glial populations in vivo, but expression of
CB1 receptors by non-neuronal cells has been detected by immu-
nocytochemistry in light (Moldrich and Wenger, 2000) and elec-
tron (Rodrı´guez et al., 2001) microscope studies. In addition, an
“atypical” location of CB1 receptor in white matter in non-
neuronal cells and in subventricular zones, where glial prolifera-
tion occurs, has been described during rat brain development
(Berrendero et al., 1998). Our study reports that cells of the
oligodendrocyte lineage express cannabinoid CB1 receptors at
lower levels than neurons. However, CB1 receptor immunoreac-
tivity in the white matter is associated mostly with postnatal and
adult brain oligodendrocytes. This agrees with results obtained
from the in vitro study. We found that cultured progenitors and
differentiated oligodendrocytes expressed CB1 receptor protein
and mRNA at higher levels than astrocytes and microglia. Ex-
pression of functional cannabinoid receptors in oligodendroglial
cells was not explored previously, but cultured astrocytes and
microglia are known to express receptors and respond to canna-
binoid stimulation (Bouaboula et al., 1995a; Cabral et al., 2001;
Molina-Holgado et al., 2002).
Synthetic and endogenous cannabinoids diminish neuronal cell
death in models of ischemia or traumatic brain injury (Nagayama
et al., 1999; Panikashvili et al., 2001). In culture, cannabinoids
reduce the vulnerability of neurons to hypoxia, glucose depriva-
tion, and excitotoxicity (Shen and Thayer, 1998; Nagayama et al.,
1999). Together with neurodegenerative diseases, myelin disor-
Figure 7. The prosurvival action of cannabinoids in oligodendrocyte
progenitors requires PI3K. Oligodendrocyte progenitors were cultured in
serum-free defined medium plus 5 ng/ml PDGF/bFGF (controls, CTL), or
cells were switched overnight (12 hr) to DMEM/F12 with or without
HU210 (500 nM), ()-Win 55,212-2 (25 nM), and the PI3K inhibitor
LY294002 (10 M). A, The effect of cannabinoids on Akt and GSK-3
phosphorylation was examined in the presence of LY294002 by Western
blot. Whole-cell lysates were prepared and immunoblotted as described in
Materials and Methods with antibodies that recognize phospho-Akt
(Ser 473), phospho-GSK-3 (Ser 9), and total GSK-3. The densitometric
data of the ratio P-GSK-3/GSK-3 represent the means  SEM of three
independent experiments performed in duplicate. B, The effect of can-
nabinoids on oligodendrocyte progenitor survival was established by the
MTT assay and by a count of A2B5-positive progenitors. Values are
expressed as a percentage of control. The MTT data are the means 
SEM of four independent experiments performed in triplicate. Quantifi-
cation of A2B5-positive oligodendrocyte progenitors was obtained from
4
eight coverslips (5 microscopic fields/coverslip), and results are the
means  SEM of four independent cultures. *p  0.001 versus control
cells; #p  0.001 versus cultures deprived of trophic support (DMEM/
F12); p  0.001 versus cultures treated with HU210 or ()-Win
55,212-2.
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ders affecting oligodendrocytes are among the major CNS pa-
thologies. Oligodendrocytes are highly vulnerable to hypoxia–
ischemia (Back et al., 2002), oxidative stress (Back et al., 1998),
and humoral and cellular immune-mediated attack (Zhou et al.,
1998; Molina-Holgado et al., 2001). However, oligodendrocyte
progenitors exist in mature CNS and are recruited to demyeli-
nated areas in experimental demyelination and in multiple scle-
rosis to remyelinate naked axons (Keirstead and Blakemore,
1999; Chang et al., 2000). On this basis, the identification of
endogenous signals promoting oligodendrocyte progenitor sur-
vival may contribute to developing reparative strategies in demy-
elinating diseases. Oligodendrocyte progenitors undergo apopto-
sis in vivo, apparently as a result of a competition for limiting
amounts of survival signals (Barres et al., 1992), and in culture
after the removal of growth/trophic factors (Barres et al., 1993;
Yasuda et al., 1995). Hence in the present study the withdrawal of
growth factors and hormones customarily added to the culture
medium resulted in a prominent oligodendrocyte progenitor
death. Interestingly, trophic deprivation-induced cell death was
prevented significantly by cannabinoids. Regarding signaling
mechanisms involved in such anti-apoptotic effect, we found that
cell death was accompanied by downregulation of the PI3K/Akt
signaling pathway and that cannabinoids promoted a significant
recovery of Akt activity. In fact, cannabinoids induced Akt phos-
phorylation in a LY294002- and wortmannin-sensitive manner,
and these PI3K inhibitors also blocked the protection conferred
by cannabinoids, suggesting that the prosurvival action of canna-
binoids depends on PI3K/Akt signaling.
Previous studies have shown a critical role of the PI3K/Akt
pathway in oligodendrocyte progenitor survival (Vemuri and
McMorris, 1996; Ebner et al., 2000). In this way, expression of a
dominant negative form of Akt induces apoptosis of oligoden-
drocyte progenitors and blocks the protective effects of various
survival signals not only after growth factor withdrawal (Flores et
al., 2000) but also in TNF--mediated toxicity (Takano et al.,
2000). Indeed, several well known prosurvival factors for oligo-
dendrocyte progenitors such as insulin, PDGF, insulin-like
growth factor-I, and others (Barres et al., 1993; Flores et al., 2000)
are also strong activators of PI3K/Akt. Therefore, the ability of
cannabinoids to activate the prosurvival PI3K/Akt pathway may
account for their protective role. Several reports have established
that the PI3K/Akt pathway promotes cell survival by both en-
hancing the expression of anti-apoptotic proteins and inhibiting
the activity of proapoptotic ones. Direct intracellular targets of
PI3K/Akt involved in the control of apoptosis have been identi-
fied in different cell types and include Bad, caspase-9, transcrip-
tion factors of the Forkhead family, the IB kinase, and GSK-3
(for review, see Brunet et al., 2001). Studies reporting down-
stream PI3K/Akt signaling in oligodendrocytes are scarce, but an
anti-apoptotic role of PI3K/Akt via Bad phosphorylation has
been described after growth factor deprivation (Flores et al.,
2000; Soane et al., 2001). Here, to determine downstream events
involved in PI3K/Akt signaling, we focused on GSK-3. This
enzyme is phosphorylated by Akt at Ser-9, and its phosphoryla-
Figure 8. The prosurvival action of cannabinoids is blocked by coincu-
bation with CB1 and CB2 receptor antagonists. Oligodendrocyte progen-
itors were cultured in serum-free defined medium plus 5 ng/ml PDGF/
bFGF (control, CTL), or cells were switched to DMEM/F12 with or
without cannabinoids for 12 hr. Cell viability was monitored by MTT
assay and by quantification of A2B5-positive oligodendrocyte progenitors.
A, Effect of the CB1 receptor antagonist SR141716A (1 M) on the
protective action of HU210 (500 nM), ()-Win 55,212-2 (25 nM), or
ACEA (20 nM). B, Effects of coincubation of SR141716A (1 M) and the
selective CB2 receptor antagonist SR144528 (1 M) on the prosurvival
action of HU210 (500 nM). Values are expressed as a percentage of
control. The MTT data are the means  SEM of four independent
experiments performed in triplicate. Quantification of A2B5-positive
oligodendrocyte progenitors was obtained from eight coverslips (5 micro-
scopic fields/coverslip), and results are the means  SEM of four inde
4
pendent experiments. A, *p  0.001 versus control cells; #p  0.001
versus cultures deprived of trophic support (DMEM/F12); p  0.001
versus cultures treated with ACEA. B, *p  0.001 versus control cells;
#p 0.01 and ##p 0.001 HU210-treated cells versus cultures deprived
of trophic support (DMEM/F12); p  0.01 and p  0.001 cultures
coincubated with CB1 and CB2 antagonists versus HU210-treated cells.
9750 J. Neurosci., November 15, 2002, 22(22):9742–9753 Molina-Holgado et al. • Cannabinoids Prevent Oligodendrocyte Progenitor Apoptosis
tion inhibits its kinase activity (Cross et al., 1995). We report that
cannabinoids increased Akt and GSK-3 phosphorylation and
that PI3K inhibitors blocked such effects, thus suggesting that
GSK-3 phosphorylation is dependent on upstream Akt activa-
tion by PI3K. Although no studies on GSK-3 expression in
oligodendrocytes are available, it is known that apoptotic stimuli
cause increased activation and nuclear translocation of GSK-3 in
different cell types, including neurons (Hetman et al., 2000;
Elyaman et al., 2002). In fact, inhibition of GSK-3 activity blocks
apoptosis of neurons, whereas overexpression of active GSK-3
or transfection with a GSK-3 mutant that cannot be phosphor-
ylated (inhibited) induces apoptosis (Hetman et al., 2000; Culbert
et al., 2001). The nature of GSK-3 effector pathways that are
relevant to cell protection remains poorly defined, but it has been
proposed that phosphorylation of Tau (Culbert et al., 2001; Elya-
man et al., 2002) and of translation initiation factor 2B by active
GSK-3 contributes to the control of cell survival, acting up-
stream of mitochondrial cytochrome c release (Pap and Cooper,
2002). Our results, demonstrating phosphorylation of GSK-3 in
a PI3K inhibitor-sensitive manner after protective cannabinoid
treatment, are consistent with PI3K/Akt/GSK-3 prosurvival
signaling in oligodendrocyte progenitors.
Based on the use of the selective CB1 agonist ACEA, the
experiments in this study indicate that the stimulation of CB1
receptors activate the PI3K/Akt signaling pathway, which results
in a prosurvival effect in cultured oligodendrocyte progenitors.
Hence the effects of ACEA were abrogated completely by the
selective CB1 antagonist SR141716A. Therefore, the presence of
active CB1 receptors and the involvement of CB1 receptors in the
cannabinoid-mediated anti-apoptotic effects in oligodendrocyte
progenitors seem clear. However, the effects of the nonselective
agonists HU210 and ()-Win 55212-2 on Akt phosphorylation
were inhibited only partially by the CB1 receptor antagonist
SR141716A. Accordingly, the blockage of CB1 receptors alone
did not abolish their protective effects. Instead, treatment of the
cultures with both SR141716A and the selective CB2 receptor
antagonist SR144528 prevented the prosurvival action of canna-
binoids. Such pharmacological action of the CB2 receptor antag-
onist SR144528 is supported by the expression of CB2 receptor
protein found in cultured progenitors and differentiated oligoden-
drocytes. Therefore, these results suggest that, in addition to CB1
receptors, oligodendrocyte progenitors express cannabinoid CB2
receptors for which the stimulation also could be involved in cell
survival after deprivation of trophic support. Although unex-
pected according to the peripheral location of CB2 receptors, this
observation agrees with reports indicating the presence of CB2
receptors in other glial cells. Cultured microglia express CB2
receptors (Carlisle et al., 2002), astrocytes are known to possess
G-protein-coupled receptors activated by cannabinoids distinct
from the CB1 receptor (Berrendero et al., 1998; Sagan et al.,
1999), and the expression of CB2 receptors also has been found in
human astrocytomas and in cultured C6 glioma cells (Galve-
Roperh et al., 2000). In addition, the presence of receptors other
than CB1 or CB2, tentatively termed CB3 receptors, which are
sensitive to SR141716A and responsive to ()-Win 55212-2 and
anandamide, has been postulated recently, thus increasing the
cannabinoid receptor heterogeneity (Howlett et al., 2002).
Limited clinical studies have suggested that cannabis might
ameliorate the symptomatology in multiple sclerosis patients
(Williamson and Evans, 2000), and beneficial effects of synthetic
cannabinoids have been reported in vivo in rodent models of
multiple sclerosis (Lyman et al., 1989; Achiron et al., 2000; Baker
et al., 2000). Apart from their actions on motor and pain path-
ways, cannabinoids regulate the immune response by reducing the
production of inflammatory mediators by leukocytes (Klein et al.,
2000), astrocytes (Molina-Holgado et al., 2002), and microglia
(Puffenbarger et al., 2000; Cabral et al., 2001), which may con-
tribute to their beneficial effects. The results of the present study
also point to a direct role of cannabinoids in promoting the
survival of oligodendrocyte progenitors, particularly in unfavor-
able conditions, as would be the case in demyelinating diseases.
Studies in progress are aimed to evaluate the function of canna-
binoids in other models affecting oligodendroglial survival.
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